GTC
ZYME icon

Ghost Tree Capital’s Zymeworks ZYME Stock Holding History

Ghost Tree Capital’s Portfolio ZYME Stock Details ZYME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-275,000
Closed -$6.05M – 51
2019
Q2 		$6.05M Buy
+275,000
New +$5.05M 1.25% 25

Other funds holding ZYME

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Ghost Tree Capital's ZYME Position: Q3 2019 in Review

Ghost Tree Capital sold out of Zymeworks (ZYME) in Q3 2019, closing a stake of 275,000 shares — an estimated $6.05M sold.

Ghost Tree Capital first reported a position in ZYME in Q2 2019 and held it in 1 quarter. The position peaked at $6.05M in Q2 2019. 74 funds tracked by Wall St. Rank hold ZYME as of Q3 2019.

  • Ghost Tree Capital reported no remaining Zymeworks position as of Q3 2019 after selling out during the quarter.
  • Ghost Tree Capital sold 275,000 Zymeworks shares in Q3 2019, an estimated $6.05M.
  • Ghost Tree Capital first reported a position in Zymeworks in Q2 2019 and held it in 1 quarter.
  • Ghost Tree Capital's Zymeworks position peaked at $6.05M in Q2 2019.
  • 74 funds tracked by Wall St. Rank held Zymeworks as of Q3 2019.

Based on Ghost Tree Capital's 13F filing for Q3 2019, filed 14 Nov 2019.